Patents by Inventor Sarah Hymowitz
Sarah Hymowitz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220204606Abstract: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.Type: ApplicationFiled: July 12, 2021Publication date: June 30, 2022Inventors: David P Arnott, Mercedesz Balazs, Nico Ghilardi, Austin L. Gurney, Philip E. Hass, Sarah Hymowitz, James M. Lee, Wenjun Ouyang, Melissa A. Starovasnik, Yan Wu
-
Publication number: 20200377585Abstract: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.Type: ApplicationFiled: February 6, 2020Publication date: December 3, 2020Applicant: Genentech, Inc.Inventors: David P. ARNOTT, Mercedesz BALAZS, Nico GHILARDI, Austin L. GURNEY, Philip E. HASS, Sarah HYMOWITZ, James M. LEE, Wenjun OUYANG, Melissa A. STAROVASNIK, Yan WU
-
Publication number: 20170291940Abstract: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.Type: ApplicationFiled: November 23, 2016Publication date: October 12, 2017Inventors: David P. ARNOTT, Mercedes Z. BALAZS, Nico GHILARDI, Austin L. GURNEY, Philip E. HASS, Sarah HYMOWITZ, James M. LEE, Wenjun OUYANG, Melissa A. STAROVASNIK, Yan WU
-
Publication number: 20130165383Abstract: The disclosure provides Apo-2 ligand variant polypeptides. Methods of making and chemically modifying Apo-2 ligand variant polypeptides are also provided. In addition, formulations of Apo-2 ligand variant polypeptides are provided. In addition, therapeutic methods for using Apo-2 ligand variant polypeptides are provided.Type: ApplicationFiled: April 6, 2012Publication date: June 27, 2013Applicant: Genentech, Inc.Inventors: Robert F. Kelley, Sarah Hymowitz
-
Publication number: 20120165267Abstract: The disclosure provides Apo-2 ligand variant polypeptides. Methods of making and chemically modifying Apo-2 ligand variant polypeptides are also provided. In addition, formulations of Apo-2 ligand variant polypeptides are provided. In addition, therapeutic methods for using Apo-2 ligand variant polypeptides are provided.Type: ApplicationFiled: June 6, 2011Publication date: June 28, 2012Applicant: Genentech, Inc.Inventors: Robert F. Kelley, Sarah Hymowitz, Stephanie Ho Lindstrom
-
Publication number: 20120077740Abstract: Methods of making Apo-2 ligand and formulations of Apo-2 ligand using divalent metal ions are provided. Such divalent metal ions include zinc and cobalt which improve Apo-2 ligand trimer formation and stability. The crystal structure of Apo-2 ligand is also provided, along with Apo-2 ligand variant polypeptides identified using oligonucleotide-directed mutagenesis.Type: ApplicationFiled: December 10, 2010Publication date: March 29, 2012Applicant: Genentech, Inc.Inventors: Avi J. Ashkenazi, Sarah Hymowitz, Robert F. Kelley, Iphigenia Koumenis, Woon-Lam Susan Leung, Mark O'Connell, Roger Pai, Zahra Shahrokh, Laura Simmons
-
Publication number: 20110256126Abstract: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.Type: ApplicationFiled: March 2, 2011Publication date: October 20, 2011Inventors: David P. Arnott, Mercedes Z. Balazs, Nico Ghilardi, Austin L. Gurney, Philip E. Haas, Sarah Hymowitz, James M. Lee, Wenjun Ouyang, Melissa A. Starovasnik, Yan Wu
-
Publication number: 20110028688Abstract: The present disclosure provides crystals of and structural coordinates of mOX40L, hOX40L, hOX40 receptor and complexes thereof. The crystals and crystal structures are useful, for example, in the design and synthesis of modulators of mOX40L, hOX40L, and/or hOX40 receptor.Type: ApplicationFiled: June 19, 2007Publication date: February 3, 2011Applicant: GENENTECH, INC.Inventors: Sarah Hymowitz, Deanne Compaan McGuinn
-
Patent number: 7855066Abstract: Methods of making Apo-2 ligand and formulations of Apo-2 ligand using divalent metal ions are provided. Such divalent metal ions include zinc and cobalt which improve Apo-2 ligand trimer formation and stability. The crystal structure of Apo-2 ligand is also provided, along with Apo-2 ligand variant polypeptides identified using oligonucleotide-directed mutagenesis.Type: GrantFiled: September 28, 2006Date of Patent: December 21, 2010Assignee: Genentech, Inc.Inventors: Avi J. Ashkenazi, Sarah Hymowitz, Robert F. Kelley, Iphigenia Koumenis, Woon-Lam Susan Leung, Mark O'Connell, Roger Pai, Zahra Shahrokh, Laura Simmons
-
Publication number: 20070218069Abstract: Anti-polyubiquitin monoclonal antibodies, and methods for using the antibodies, are provided.Type: ApplicationFiled: December 14, 2006Publication date: September 20, 2007Inventors: Nathaniel Gordon, Robert Kelley, Anh Pham, Sarah Hymowitz
-
Publication number: 20070161564Abstract: Methods of making Apo-2 ligand and formulations of Apo-2 ligand using divalent metal ions are provided. Such divalent metal ions include zinc and cobalt which improve Apo-2 ligand trimer formation and stability. The crystal structure of Apo-2 ligand is also provided, along with Apo-2 ligand variant polypeptides identified using oligonucleotide-directed mutagenesis.Type: ApplicationFiled: November 22, 2006Publication date: July 12, 2007Applicant: Genentech, Inc.Inventors: Avi Ashkenazi, Sarah Hymowitz, Robert Kelley, Iphigenia Koumenis, Woon-Lam Leung, Mark O'Connell, Roger Pai, Zahra Shahrokh, Laura Simmons
-
Publication number: 20070160576Abstract: The present invention is directed to a novel naturally occurring human cytokine that is comprised of a heterodimer of interleukin-17 and interleukin-17F designated herein as interleukin 17A/F (IL-17A/F). Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, specific antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.Type: ApplicationFiled: November 29, 2006Publication date: July 12, 2007Applicant: Genentech, Inc.Inventors: David Arnott, Mercedesz Balazs, Nico Ghilardi, Austin Gurney, Philip Hass, Sarah Hymowitz, James Lee, Wenjun Ouyang, Melissa Starovasnik, Yan Wu
-
Publication number: 20070098681Abstract: The disclosure provides Apo-2 ligand variant polypeptides. Methods of making and chemically modifying Apo-2 ligand variant polypeptides are also provided. In addition, formulations of Apo-2 ligand variant polypeptides are provided. In addition, therapeutic methods for using Apo-2 ligand variant polypeptides are provided.Type: ApplicationFiled: October 2, 2006Publication date: May 3, 2007Applicant: Genentech, Inc.Inventors: Robert Kelley, Sarah Hymowitz, Stephanie Lindstrom
-
Publication number: 20070020735Abstract: The present invention is directed to novel polypeptides having sequence identity with IL-17, IL-17 receptors and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided herein are methods for treating degenerative cartilaginous disorders and other inflammatory diseases.Type: ApplicationFiled: September 29, 2006Publication date: January 25, 2007Inventors: Jian Chen, Ellen Filvaroff, Sherman Fong, Dorothy French, Audrey Goddard, Paul Godowski, J. Grimaldi, Austin Gumey, Kenneth Hillan, Sarah Hymowitz, Hanzhong Li, James Pan, Melissa Starovasnik, Daniel Tumas, Menno Lookeren, Richard Vandlen, Colin Watanabe, P. Williams, William Wood, Daniel Yansura
-
Publication number: 20060141561Abstract: The disclosure provides Apo-2 ligand variant polypeptides. Methods of making and chemically modifying Apo-2 ligand variant polypeptides are also provided. In addition, formulations of Apo-2 ligand variant polypeptides are provided. In addition, therapeutic methods for using Apo-2 ligand variant polypeptides are provided.Type: ApplicationFiled: June 23, 2003Publication date: June 29, 2006Inventors: Robert Kelley, Sarah Hymowitz